Metabiomed메타바이오메드
059210 · KOSDAQ · ₩059210 · 메타바이오메드
₩3,625▼ ₩10 (0.28%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩103B | ₩94B | ₩83B | ₩69B | ₩59B |
| Cost of sales | ₩49B | ₩47B | ₩45B | ₩40B | ₩34B |
| Gross profit | ₩54B | ₩47B | ₩38B | ₩29B | ₩25B |
| Operating income | ₩21B | ₩17B | ₩11B | ₩5.3B | ₩4.9B |
| Net income | ₩11B | ₩22B | ₩9.8B | ₩3.6B | ₩9.7B |
| Net income to shareholders | ₩11B | ₩22B | ₩10B | ₩2.6B | ₩9.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩187B | ₩177B | ₩130B | ₩121B | ₩103B |
| Current assets | ₩83B | ₩94B | ₩50B | ₩51B | ₩48B |
| Cash and equivalents | ₩18B | ₩15B | ₩11B | ₩13B | ₩10B |
| Total liabilities | ₩62B | ₩81B | ₩57B | ₩58B | ₩43B |
| Current liabilities | ₩60B | ₩74B | ₩44B | ₩45B | ₩38B |
| Borrowings | ₩42B | ₩5.6B | ₩44B | ₩44B | ₩34B |
| Total equity | ₩125B | ₩96B | ₩73B | ₩63B | ₩60B |
| Shareholders' equity | ₩124B | ₩93B | ₩70B | ₩61B | ₩58B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩20B | ₩23B | ₩10B | ₩9.2B | ₩11B |
| Capital spending | ₩20B | ₩11B | ₩11B | ₩15B | ₩2.1B |
| Free cash flow | −₩471M | ₩12B | −₩1.3B | −₩6.2B | ₩9.1B |
| Dividends paid | ₩685M | ₩457M | ₩457M | ₩458M | ₩229M |
Consolidated where available. Amounts in won.
Also known as: Metabiomed / 메타바이오메드 / 059210 / KRX:059210
Source: KRX statistical information